256 related articles for article (PubMed ID: 11849448)
1. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Degenhardt TP; Alderson NL; Arrington DD; Beattie RJ; Basgen JM; Steffes MW; Thorpe SR; Baynes JW
Kidney Int; 2002 Mar; 61(3):939-50. PubMed ID: 11849448
[TBL] [Abstract][Full Text] [Related]
2. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.
Alderson NL; Chachich ME; Youssef NN; Beattie RJ; Nachtigal M; Thorpe SR; Baynes JW
Kidney Int; 2003 Jun; 63(6):2123-33. PubMed ID: 12753299
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats.
Figarola JL; Scott S; Loera S; Xi B; Synold T; Rahbar S
Ann N Y Acad Sci; 2005 Jun; 1043():767-76. PubMed ID: 16037304
[TBL] [Abstract][Full Text] [Related]
4. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Alderson NL; Chachich ME; Frizzell N; Canning P; Metz TO; Januszewski AS; Youssef NN; Stitt AW; Baynes JW; Thorpe SR
Diabetologia; 2004 Aug; 47(8):1385-95. PubMed ID: 15309289
[TBL] [Abstract][Full Text] [Related]
5. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors.
Figarola JL; Scott S; Loera S; Xi B; Synold T; Weiss L; Rahbar S
Diabetes Metab Res Rev; 2005; 21(6):533-44. PubMed ID: 15818713
[TBL] [Abstract][Full Text] [Related]
6. Novel inhibitors of glycation and AGE formation.
Rahbar S
Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
[TBL] [Abstract][Full Text] [Related]
7. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.
Metz TO; Alderson NL; Chachich ME; Thorpe SR; Baynes JW
J Biol Chem; 2003 Oct; 278(43):42012-9. PubMed ID: 12923193
[TBL] [Abstract][Full Text] [Related]
8. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal.
Nagaraj RH; Sarkar P; Mally A; Biemel KM; Lederer MO; Padayatti PS
Arch Biochem Biophys; 2002 Jun; 402(1):110-9. PubMed ID: 12051689
[TBL] [Abstract][Full Text] [Related]
9. Pyridoxamine inhibits maillard reactions in diabetic rat lenses.
Padival S; Nagaraj RH
Ophthalmic Res; 2006; 38(5):294-302. PubMed ID: 16974131
[TBL] [Abstract][Full Text] [Related]
10. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Soulis-Liparota T; Cooper ME; Dunlop M; Jerums G
Diabetologia; 1995 Apr; 38(4):387-94. PubMed ID: 7796978
[TBL] [Abstract][Full Text] [Related]
11. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.
Figarola JL; Scott S; Loera S; Tessler C; Chu P; Weiss L; Hardy J; Rahbar S
Diabetologia; 2003 Aug; 46(8):1140-52. PubMed ID: 12845431
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective effects of a novel inhibitor of advanced glycation.
Forbes JM; Soulis T; Thallas V; Panagiotopoulos S; Long DM; Vasan S; Wagle D; Jerums G; Cooper ME
Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Cameron NE; Gibson TM; Nangle MR; Cotter MA
Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Metz TO; Alderson NL; Thorpe SR; Baynes JW
Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
[TBL] [Abstract][Full Text] [Related]
15. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
[TBL] [Abstract][Full Text] [Related]
16. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation.
Wu ET; Liang JT; Wu MS; Chang KC
Exp Gerontol; 2011 Jun; 46(6):482-8. PubMed ID: 21316441
[TBL] [Abstract][Full Text] [Related]
17. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats.
Soulis T; Cooper ME; Sastra S; Thallas V; Panagiotopoulos S; Bjerrum OJ; Jerums G
Diabetologia; 1997 Oct; 40(10):1141-51. PubMed ID: 9349594
[TBL] [Abstract][Full Text] [Related]
18. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats.
Nyengaard JR; Chang K; Berhorst S; Reiser KM; Williamson JR; Tilton RG
Diabetes; 1997 Jan; 46(1):94-106. PubMed ID: 8971088
[TBL] [Abstract][Full Text] [Related]
19. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.
Degenhardt TP; Fu MX; Voss E; Reiff K; Neidlein R; Strein K; Thorpe SR; Baynes JW; Reiter R
Diabetes Res Clin Pract; 1999 Feb; 43(2):81-9. PubMed ID: 10221660
[TBL] [Abstract][Full Text] [Related]
20. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
